At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 226 enrolled
Drug / intervention
AGN-241751 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating AGN-241751 and Placebo for Major Depressive Disorder. Completed, enrolled 226 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedOct 31, 2018
Enrollment StartNov 8, 2018
Primary CompletionOct 23, 2019
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.7 years ago
Interventions
AGN-241751drug
AGN-241751 is supplied in tablet form
Placebodrug
Placebo is supplied in tablet form